Lung Cancer Non Small Cell clinical trials

Explore recruiting lung cancer non small cell clinical trials.

Recruiting lung cancer non small cell studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lung Cancer Non Small Cell trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung Cancer

Portugal, Hungary, Italy, Belgium, Germany, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, locally advanced, unresectable or metastatic PD-L1 selected non small cell lung cancer (GALAXIES LUNG 301)

Italy, Belgium, Romania, Portugal, Netherlands, Finland +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL 1L)

Netherlands, Poland, Hungary, Romania, Germany, Bulgaria +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG)

Belgium, France, Greece, Italy, Finland, Netherlands +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Germany, Romania, Italy, France, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Lung Cancer Non Small Cell trials by city

Lung Cancer Non Small Cell in Toronto Lung Cancer Non Small Cell in Vancouver Lung Cancer Non Small Cell in Montreal Lung Cancer Non Small Cell in Calgary Lung Cancer Non Small Cell in Edmonton Lung Cancer Non Small Cell in Ottawa Lung Cancer Non Small Cell in Winnipeg Lung Cancer Non Small Cell in Quebec City Lung Cancer Non Small Cell in Hamilton Lung Cancer Non Small Cell in Kitchener Lung Cancer Non Small Cell in London Lung Cancer Non Small Cell in Halifax Lung Cancer Non Small Cell in New York Lung Cancer Non Small Cell in Los Angeles Lung Cancer Non Small Cell in Chicago Lung Cancer Non Small Cell in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease